Behavior of bladder cancer in Matanzas from December 2014 to January 2020
Keywords:
Key words, Bladder cancer, Immunotherapy, chemotherapy, Recurrence.Abstract
Cancer of the bladder (CV) is the second urological neoplasm. In Cuba it constitutes the seventh cause of cancer in males and among the first fifteen, when both sexes are combined.
Objective: To evaluate the behavior of bladder cancer (CV) in patients of the Faustino Pérez Hernández Hospital.
Materials and methods: An observational, descriptive and cross-sectional study was carried out in the period from December 2014 to January 2020. The patients were divided into 3 groups treated with Minimum Access Surgery (CMA), Open Surgery (CA) and No Operated (NO), the histological groups and tumor staging were described and treatment was applied according to the service protocol, their complications and the presence of tumor recurrences were also described.Universe: 222 patients diagnosed with bladder cancer were included in the study.
Results: It was found that the greatest number of patients diagnosed with CV are male, the histological type is low-grade urothelial cell carcinoma and stage T1. Recurrences occurred before 5 years in 10.8% of cases. 196 patients presented complications.
Conclusions:
The CV is more frequent in the ages between 60 to 69 years, the recurrences appeared mainly between 1 and three years. Complications occurred in 196 patients, with Surgery being the therapeutic modality with the highest percentage with 32.22% and infections being the most frequent complications.
Downloads
References
1.Mark R, Meihua Wang G, Kenneth D,et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. J Clin Oncology [Internet]. 2013; 31:32, 4085-4091.Disponible en: https://ascopubs.org/doi/full/10.1200/JCO.2013.49.6968
2. Arjun V, Balar Andrea B, Apolo Irina O, et al. Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer. J Clinical Oncology [Internet]. 2013[citado 11/11/2019]; 31(6):724-730.Disponible en : https://ascopubs.org/doi/full/10.1200/JCO.2012.42.5215
3. Apolo AB, Ostrovnaya I, Halabi S, et al. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst. 2013 Apr 3;105(7):499-503. Citado en PMID; PMCID: 3691944.
4. American Cáncer Society. Cáncer de vejiga [Internet]. [citado 11/11/2019];2016. Disponible en: http://www.cancer.org/acs/groups/cid/documents/webcontent/002280-pdf.pdf
5. Páez A, Lujan M, Martin E, et al. Alternativas al control cistoscópico de los tumores vesicales. Archivos Españoles Urología 2016; 50: 1.079-1.083.
6. Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. Eur Urol. 2018 Dec;74(6):784-795.Citado en Pub Med; PMID: 30268659.
7. Ministerio de Salud Pública. Dirección de registros médicos y estadísticas de salud. Anuario estadístico de salud 2016[Internet]. La Habana: Ministerio de Salud Pública [citado 11/11/2019];2017. Disponible en: https://files.sld.cu/dne/files/2017/05/Anuario_Estad%C3%ADstico_de_Salud_e_2016_edici%C3%B3n_2017.pdf
8. Cabrera Cabrera JA, Cabrera López I, Domínguez Gordillo A, et al. Cáncer de vejiga en hospitales públicos de Madrid. Sanid Mil [Internet]. 2014 [citado 12/12/ 2019] ; 70(3): 197-203. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1887-85712014000300010&lng=es
9. Pujada Álvarez MM, Zamora Rosales A, Amador González RM. Enfoque multidisciplinario del cáncer de vejiga en Pinar del Río. Rev Ciencias Médicas de Pinar del Río [Internet]. 2019 [citado 27/07/ 2019]; 23(2): 174-186. Disponible en: http://revcmpinar.sld.cu/index.php/publicaciones/article/view/3843
10. Antoni S, Ferlay J, Soerjomataram I, et al. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2017 Jan;71(1):96-108. Citado en PubMed; PMID: 27370177.
11. Sierra Pérez L, Morales Yera RA, Ibáñez Carrillo E. Quimioterapia neoadyuvante con metotrexato, vinblastina, adriamicina y cisplatino en el tratamiento del carcinoma vesical irresecable. Medicentro Electrónica [Internet]. 2018 [citado12/12/ 2019] ; 22(2): 165-168. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30432018000200011&lng=es
12. D'Andrea D, Shariat SF. Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement. Eur Urol. 2017 Sep;72(3):474-75.Citado en PubMed; PMID: 28599913.
13. Hernández-Fernández C, Herranz-Amo F, Moralejo-Gárate M, et al. Cáncer vesical infiltrante: factores pronósticos, seguimiento y tratamiento de las recidivas. Actas Urológicas Españolas [Internet]. 2016 [citado 27/07/ 2019]; 41(6): 352-358.Disponible en:https://www.elsevier.es/es-revista-actas-urologicas-espanolas-292-articulo-cancer-vesical-infiltrante-factores-pronosticos-S021048061630119X
14. Nieder AM, Meinbach DS, Kim SS, et al. Transurethral bladder tumor resection: intraoperative and postoperative complications in a residency setting. J Urol. 2005 Dec;174(6):2307-9. Citado en PubMed; PMID: 16280830.
15.Donald G, Skinner E, David Crawford D, et al. Complications of Radical Cystectomy for Carcinoma of the Bladder. J of Urology [Internet]. 1980 [citado 11/10/2019]; 123(5):640-643. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0022534717560735
16. Collado A, Chéchile GE, Salvador J, et al. Early complications of endoscopic treatment for superficial bladder tumors. J Urol. 2000 Nov;164(5):1529-32. Citado en PubMed;PMID: 11025697.
17. Subirá-Ríos D, Herranz-Amo F, Moralejo-Gárate M, et al. Complicaciones posquirúrgicas en los pacientes con cáncer de vejiga tratados con cistectomía: Diferencias entre el abordaje abierto y laparoscópico. Actas Urológicas Españolas [Internet]. 2019 [citado 11/07/2019];43(5):305-313.Disponible en: https://www.elsevier.es/es-revista-actas-urologicas-espanolas-292-articulo-complicaciones-posquirurgicas-pacientes-con-cancer-S0210480619300063
18. Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol. 2006;175(6):2004-10.Citado en PubMed; PMID:16697786.
Published
How to Cite
Issue
Section
License
All content published in this journal is Open Access, distributed under the terms of the CC BY-NC 4.0 License.
It allows:
- Copy and redistribute published material in any medium or format.
- Adapt the content.
This will be done under the following terms:
- Attribute the authors' credits and indicate whether changes were made, in which case it must be in a reasonable way.
- Non-commercial use.
- Recognize the journal where it is published.
The copyrights of each article are maintained, without restrictions.
Guidelines to authors
